Form 8-K
8-K — Celularity Inc
Accession: 0001493152-26-049203
Filed: 2026-10-29
Period: 2026-10-29
CIK: 0001752828
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Other Events
Item: Financial Statements and Exhibits
Documents
8-K — form8-k.htm (Primary)
EX-99.1 (ex99-1.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: form8-k.htm · Sequence: 1
false
0001752828
0001752828
2026-10-29
2026-10-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 29, 2026
Celularity
Inc.
(Exact
name of registrant as specified in its charter)
Delaware
001-38914
83-1702591
(State
or other jurisdiction
of
incorporation)
(Commission
File
Number)
(IRS
Employer
Identification
No.)
170
Park Ave
Florham
Park, New Jersey
07932
(Address
of principal executive offices)
(Zip
Code)
Registrant’s
telephone number, including area code: (908) 768-2170
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instructions A.2. below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Class
A Common Stock, $0.0001 par value per share
CELU
The
Nasdaq Stock Market LLC
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events.
On
October 29, 2026, Celularity Inc. (“Celularity”) issued a press release announcing an exclusive manufacturing and commercial
collaboration with Vesalius Longevity Labs Inc. (“Vesalius”), for U.S.-based purification, processing, analytical testing
and manufacture of peptide active pharmaceutical ingredients under Vesalius’s Peptual® brand.
The
collaboration pairs Celularity’s manufacturing infrastructure and technical expertise with Vesalius’s Peptual platform to
advance U.S.-based production of peptide APIs in accordance with current good manufacturing practice standards at Celularity’s
New Jersey facility. The parties intend to establish a domestic supply platform that supports consistent product quality and lot-level
traceability while strengthening the resilience and accountability of the peptide API supply chain.
A
copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
99.1
Press release issued by Celularity Inc. on October 29, 2026.
104
Cover
Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
CELULARITY
INC.
Dated:
October 29, 2026
By:
/s/
K. Harold Fletcher
Name:
K.
Harold Fletcher
Title:
Chief
Legal and Strategy Officer
EX-99.1
EX-99.1
Filename: ex99-1.htm · Sequence: 2
Exhibit
99.1
Celularity
and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States
Celularity
to serve as the exclusive partner for the finish manufacturing of Vesalius’s Peptual peptide APIs, supporting Vesalius’s
expansion into pharmaceutical ingredient supply
Collaboration
advances Celularity’s regenerative longevity vision and creates an opportunity to expand revenue through its U.S. manufacturing
infrastructure and technical expertise
FLORHAM
PARK, N.J. and SCOTTSDALE, A.Z., October 29, 2026—Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused
regenerative and cellular medicine company, and Vesalius Longevity Labs Inc. (“Vesalius”), a leading, global peptide and
longevity brand, today announced that they have entered into an exclusive manufacturing agreement to establish a dedicated, first-of-its-kind,
U.S. final stage API manufacturing and supply platform for Vesalius’s Peptual-branded active pharmaceutical ingredients (“APIs”).
The
collaboration expands Celularity’s regenerative longevity platform by applying Celularity’s U.S.-based manufacturing infrastructure
and technical capabilities to support the development of Vesalius’s Peptual®-branded peptide APIs at its Florham Park,
New Jersey facility. It builds on Celularity’s experience manufacturing complex biologics to current good manufacturing practice
(“cGMP”) standards, extending those capabilities into peptide API manufacturing while supporting its broader vision of advancing
regenerative longevity.
Under
the collaboration, Celularity will perform downstream purification, processing, analytical testing and manufacturing activities using
supplier-provided bulk peptide material. The work is intended to establish peptide-specific manufacturing processes that satisfy cGMP
requirements, supported by defined product specifications, documented sourcing and lot-level traceability. The collaboration is intended
to position the parties to respond to potential regulatory developments affecting peptide compounding. If and when the U.S. Food and
Drug Administration (“FDA”), following its consideration of recommendations from the Pharmacy Compounding Advisory Committee
(“PCAC”), adds covered peptide substances and forms to its list of bulk drug substances that may be used in compounding under
federal law, the parties intend to supply eligible Peptual-branded APIs to appropriately licensed U.S. compounding pharmacies. The collaboration
will not involve manufacturing GLP-1 receptor agonists or other weight-loss peptides, as these products are excluded from Vesalius’s
business model.
“Peptides
represent an important category of products which can work to augment the clinical utility of conventional therapeutics, and we believe
can complement our regenerative cellular products,” said Robert J. Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer
of Celularity. “We have invested in a purpose-built U.S. facility and assembled a team with experience manufacturing complex medicines.
As such, our collaboration with Vesalius represents an important business opportunity for Celularity and a practical extension of our
regenerative longevity strategy.”
The
collaboration comes amid regulatory scrutiny of the quality and provenance of imported pharmaceutical ingredients. The FDA has highlighted
concerns about peptide APIs from unverified foreign sources and has separately urged compounding pharmacies to verify their ingredient
suppliers, understand the testing performed and identify the original API manufacturer. Celularity and Vesalius believe these concerns
create an imperative for a domestic manufacturing platform to strengthen pharmaceutical supply-chain resilience and U.S. national health
preparedness. By bringing key downstream manufacturing activities onshore, the collaboration is intended to establish a more transparent
path from bulk peptide material through final API release.
“We
selected Celularity because its facility, technical personnel and experience manufacturing complex biological products provide a strong
foundation for our peptide API sourcing plans,” said Pradeep Albert, CEO of Vesalius. “Celularity’s capabilities complement
our Peptual platform and commercialization strategy. Together, we aim to establish a U.S. domestic supply platform supported by documented
manufacturing processes, defined quality specifications and traceability from supplier inputs through final API release.”
For
patients and prescribing physicians, uncertainty about an ingredient’s origin, identity and purity raises practical questions about
what is being supplied and the evidence supporting its quality. Meaningful transparency requires documentation connecting each lot to
its original source, the manufacturing controls applied and the testing supporting its release. The parties intend to build that accountability
into the planned platform, supporting informed sourcing decisions by pharmacies and providing a clearer basis for peptide use from prescribing
physicians and their patients.
“The
healthcare community deserves transparency about where the ingredients in medications originate and how their quality has been
evaluated,” said Micheal Roizen, M.D., former head of Wellness at Cleveland
Clinic and Chief Scientific Advisor at Vesalius. “When the original manufacturer is unclear or testing records are
incomplete, physicians and patients are left with questions that should be answered before a product is used. Vesalius’s
collaboration with Celularity is intended to bring greater visibility and accountability to that supply chain. That is an important
foundation for responsible progress in peptide medicine.”
Regulatory
Notice
The
peptides and APIs described in this release are not FDA-approved drug products. Compounded drugs are not FDA-approved and are not reviewed
by FDA for safety, effectiveness or manufacturing quality before marketing. FDA establishment registration, facility inspection, advisory
committee consideration or recommendations, cGMP terminology, a certificate of analysis or domestic manufacture does not constitute FDA
approval or endorsement of a substance, API, compounded drug, manufacturer or pharmacy. Execution of the collaboration agreement and
completion of development or qualification activities do not themselves authorize commercial release, distribution or use of any peptide
API. Availability is subject to applicable law, FDA policy and local jurisdictional requirements.
About
Vesalius Longevity Labs
Vesalius
Longevity Labs is a longevity science and regenerative health platform focused on peptides, biologics, preventative healthcare and performance
optimization. Vesalius operates a scalable B2Doctor2Consumer ecosystem designed to support healthcare providers, telehealth infrastructure,
product fulfillment and advanced longevity therapeutics across global markets. Vesalius’s expanding ecosystem includes peptide
therapeutics, regenerative medicine initiatives, royalty-generating biologics partnerships and advanced provider enablement technologies
designed to support the future of personalized health and wellness.
For
more information, visit: https://www.vesaliuslabs.com/
Vesalius
Media Contacts:
Media
Contact: vesalius@jacktaylorpr.com
About
Celularity
Celularity
Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous
cell therapies and biomaterials. Celularity’s regenerative longevity vision centers on advancing technologies intended to address
aging and age-related conditions and extend healthspan. Its purpose-built facility in Florham Park, New Jersey supports manufacturing,
research and biobanking activities. Celularity also pursues contract development and manufacturing opportunities that apply its infrastructure
and technical expertise to third-party programs.
For
more information, visit www.celularity.com.
Celularity
Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of the U.S. federal securities laws, including statements regarding
the establishment, development and potential growth of Celularity’s peptide API manufacturing business vertical; its alignment
with Celularity’s regenerative longevity strategy; the anticipated scope, implementation and benefits of the collaboration with
Vesalius; the development and qualification of manufacturing processes that satisfy applicable cGMP requirements; potential commercial
supply and revenue generation; utilization of Celularity’s existing infrastructure; and anticipated benefits relating to quality,
traceability and domestic supply-chain resilience. These statements may be identified by words such as “anticipate,” “believe,”
“expect,” “intend,” “may,” “plan,” “potential,” “will” and similar
expressions, although not all forward-looking statements contain these words.
These
forward-looking statements reflect Celularity’s current expectations and assumptions and are subject to substantial risks and uncertainties
that could cause actual results to differ materially. These risks include the parties’ ability to agree upon and fund product-specific
development plans and commercial supply terms; complete technical transfer, process development, analytical-method qualification and
manufacturing qualification; establish peptide-specific processes and quality systems that satisfy applicable cGMP requirements; achieve
required specifications and commercial scale; and obtain and maintain required regulatory authorizations, registrations and licenses.
Additional risks include uncertain customer demand, the costs of establishing the new business vertical, Celularity’s ability to
generate revenue or achieve profitable operations, and changes in laws, regulations, FDA policies or enforcement priorities affecting
peptide manufacture, distribution or compounding. Particular peptide substances or forms may not be eligible for supply or use in the
intended channels. Celularity’s existing facility and manufacturing experience do not assure successful development or commercial
manufacture of any peptide API. Commercial supply may be delayed indefinitely or may not occur.
These
risks and uncertainties should be considered together with the risks described under “Risk Factors” and elsewhere in Celularity’s
most recent Annual Report on Form 10-K, as amended, subsequent Quarterly Reports on Form 10-Q and other filings with the U.S. Securities
and Exchange Commission. The risks described are not exhaustive. Forward-looking statements speak only as of the date of this release,
and readers should not place undue reliance on them. Except as required by law, Celularity undertakes no obligation to update any forward-looking
statement to reflect subsequent events, circumstances or changes in expectations.
Celularity
Investor and Media Contact
info@celularity.com
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 7
v3.26.3
Cover
Oct. 29, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Oct. 29, 2026
Entity File Number
001-38914
Entity Registrant Name
Celularity
Inc.
Entity Central Index Key
0001752828
Entity Tax Identification Number
83-1702591
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
170
Park Ave
Entity Address, City or Town
Florham
Park
Entity Address, State or Province
NJ
Entity Address, Postal Zip Code
07932
City Area Code
(908)
Local Phone Number
768-2170
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Class
A Common Stock, $0.0001 par value per share
Trading Symbol
CELU
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration